Anesiva Inc

Anesiva — Algorx Pharmaceuticals — Merger or Acquisition (November 2005)

48 slides from Anesiva's merger presentation, Nov 16, 2005

  1. Slide 1: Creating a Late-Stage Company Focused on Pain Management and Inflammation

    Creating a Late-Stage Company Focused on Pain Management and Inflammation November 16, 2005 Prescott Group Capital Management

  2. Slide 2: Forward Looking Statements

    FORWARD LOOKING STATEMENTS This presentation includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "pla

  3. Slide 3: Forward Looking Statements (2)

    FORWARD LOOKING STATEMENTS (2) Additional Information and Where to Find It Corgentech Inc. has filed a registration statement on Form S-4, and Corgentech and AlgoRx Pharmaceuticals, Inc. have filed a related joint proxy statement/prospectus, in connection with the merger transaction involving Corgen

  4. Slide 4: AlgoRx Pharmaceuticals, Inc. / Corgentech

    Algok @ Pharmaceuticals, Inc. CORGENTECH

  5. Slide 5: Prevalence of Pain in Seven Major Countries

    Above indications are all targets of Corgentech pipeline PATIENT NUMBERS PREVALANCE OF PAIN IN SEVEN MAJOR COUNTRIES Prevalence of post-operative pain 75,068,000 Prevalence of back pain 208,996,000 Prevalence of HIV and AIDS pain 847,000 Prevalence of diabetic neuropathy pain 13,243,000 Prevalence o

  6. Slide 6: Shortcomings of Current Treatments for Pain

    SHORTCOMINGS OF CURRENT TREATMENTS FOR PAIN Slow onset of action Insufficient efficacy Occurrence of side effects Need for frequent dosing Lack of site specificity Potential to cause physical dependence

  7. Slide 7: Creating Late-Stage Company

    CREATING LATE-STAGE COMPANY Four product development programs focused on significant clinical problems with attractive market potential – Each drug has unique mechanism of action offering risk diversification – Each drug has potential for approval in multiple indications – Each drug can be commercia

  8. Slide 8: Product Pipeline

    ALGRX 3268 ALGRX 4975 * ALGRX 1207 * NF- K B Decoy * PRODUCT PIPELINE PRECLINICAL PHASE 1 PHASE 2 PHASE 3 Pre-procedural analgesia (003) Pre-procedural analgesia (004) Post-surgical pain Morton’s neuroma Tendonitis Cutaneous neuropathic pain Atopic dermatitis (eczema) * Does not reflect comprehensiv

  9. Slide 9: Delivering on Our Promises

    Report Clinical Data from Second Phase 3 Trial of ALGRX 3268 Report Clinical Data from Phase 2 Trial of ALGRX 4975 for Morton’s Neuroma Report Clinical Data from First Phase 3 Trial of ALGRX 3268 DELIVERING ON OUR PROMISES File IND for Phase 1 Trial of ALGRX 1207 for Pain Relief Report Clinical Data

  10. Slide 10: Benefits of Merging

    Combined Company Corgentech Standalone Attribute BENEFITS OF MERGING All drugs have different mechanisms All DNA-based drugs Risk Diversification Est. 2009-2010 Time to First Approval Next most advanced product Most advanced product Number of drugs in clinic or soon to enter clinic Completed multipl

  11. Slide 11: Market Capitalization: Comparable Phase 2/3 Peer Companies

    MARKET CAPITALIZATION COMPARABLE PHASE 2/3 PEER COMPANIES Nuvelo, Inc. $348 mm Pain Therapeutics $367 mm Renovis, Inc. $366 mm Rigel Pharmaceuticals, Inc. $534 mm Telik, Inc. $881 mm Threshold Pharmaceuticals, Inc. $364 mm Corgentech Inc. * $200 mm * Assumes market has incorporated merger into curre

  12. Slide 12: Seasoned Board and Management

    SEASONED BOARD AND MANAGEMENT Board – Richard Brewer , former CEO of Scios, former President of HeartPort, former SVP at Genentech – Dr. Charles Cohen , VP at Advent, former CEO of Cellzome, founder & former CEO of Creative BioMolecules – Thomas Colligan , former vice chairman of PricewaterhouseCoop

  13. Slide 13: AlgoRx Pharmaceuticals, Inc. / Corgentech

    Algok @ Pharmaceuticals, Inc. CORGENTECH

  14. Slide 14: ALGRX 3268 - Topical Local Anesthesia

    ALGRX 3268- TOPICAL LOCAL ANESTHESIA Key desirable product attributes – Sterile, pre-filled, needle-free disposable delivery system (Powderject ® ) – Rapid onset of action Within 1 minute with duration of about 10 minutes – No vasoconstriction with good dermal tolerability – Ease of use with no dres

  15. Slide 15: Positive Results from Two Phase 3 Trials

    POSITIVE RESULTS FROM TWO PHASE 3 TRIALS Primary endpoint achieved (p=0.007) – Statistically significantly less pain on needle insertion in treated group compared to placebo group assessed using FACES rating scale 574 pediatric (ages 3-18) patients at six U.S. clinical trial sites – ALGRX 3268 group

  16. Slide 16: ALGRX 3268 Onset Within One Minute vs EMLA

    ALGRX 3268 has an onset within one minute, whereas EMLA is labeled for a pretreatment period of at least one hour -30 -20 -10 Time after administration, minutes ALGRX 3268 Rapid Onset of Action Critical to Adoption of Product ALGRX 3268 Data from Phase 1 trial in 272 adults EMLA Package Insert for E

  17. Slide 17: ALGRX 3268 Development

    Protocol Age Group Phase Total Patients Primary Endpoint Status Antecubital Fossa Adults Safety and Efficacy Primary Endpoint Achieved Back of Hand Adults Safety and Efficacy Primary Endpoint Achieved Pharmacokinetics Adults Evaluate Circulating Lidocaine Primary Endpoint Achieved Antecubital Fossa

  18. Slide 18: Projected Timeline for ALGRX 3268

    PROJECTED TIMELINE FOR ALGRX 3268 Registration – File NDA in 2006 – Product approval in 2007 Regulatory – Reviewed as a drug by the FDA Analgesics and Acute Care Division

  19. Slide 19: Commercial Opportunities for ALGRX 3268

    COMMERCIAL OPPORTUNITIES FOR ALGRX 3268

  20. Slide 20: ALGRX 3268: Venipuncture Markets

    PROCEDURE NUMBERS Additional Target Market Includes the 66,000 Physician’s Offices, Clinical Labs and Blood Donation Centers in the U.S. ALGRX 3268: VENIPUNCTURE MARKETS Pediatric in-hospital procedures 18,000,000 Adult in-hospital emergency room visits 89,000,000 Hemodialysis patient visits 46,800,

  21. Slide 21: Pediatric In-Hospital Market

    PEDIATRIC IN-HOSPITAL MARKET Target market – Only 2.1MM out of 18MM venipuncture procedures in children’s hospitals and large academic institutions utilize a topical local anesthetic today Low utilization of topical local anesthetics ( 12% of pediatric procedures) due to: – slow onset of action – la

  22. Slide 22: ALGRX 3268 Drug Class Comparison

    EMLA ALGRX 3268 ALGRX 3268- DRUG CLASS COMPARISON 37% blanching, 30% erythema Minimal erythema Adverse Reactions 1-2 hours after removal 10-15 minutes Duration 60 minutes to several hours 1 minute Onset of Action Messy and requires covering Minimal Preparation Ease of Use +++ +++ Efficacy

  23. Slide 23: ALGRX 3268: Potential Pediatric Market

    POTENTIAL SALES POTENTIAL ANNUAL PROCEDURES STRAWMAN UNIT PRICE Superior Product Profile + Promotional Efforts = Market Penetration and Market Growth ALGRX 3268: POTENTIAL PEDIATRIC MARKET $60mm - $80mm 5mm $12 - $16* $72mm - $96mm 6mm $12 - $16* $48mm - $64mm 4mm $12 - $16* $36mm - $48mm 3mm $12 -

  24. Slide 24: ALGRX 3268: Phased Marketing Approach

    ALGRX 3268: PHASED MARKETING APPROACH In-hospital Pediatric 18M

  25. Slide 25: AlgoRx Pharmaceuticals, Inc. / Corgentech

    Algok @ Pharmaceuticals, Inc. CORGENTECH

  26. Slide 26: ALGRX 4975 - VR1 Anesthetic

    Capsaicin Overview Blocks noxious pain with long duration ALGRX 4975 – VR1 ANESTHETIC Administered locally at the site of pain Single administration may provide analgesia for weeks to months Non-opioid based Only reduces long-term noxious pain associated with C-neurons Does not affect other nerve fi

  27. Slide 27: ALGRX 4975 Development

    ALGRX 4975 DEVELOPMENT Protocol Phase Total Patients Primary Endpoint Status Postsurgical Pain Bunion Removal Surgery Time to Rescue Medication 72-hour Endpoint Achieved Bunion Removal Surgery Magnitude of Pain Relief 24 and 72- hour Endpoints Achieved Hernia Repair Magnitude and Duration of Pain Re

  28. Slide 28: ALGRX 4975: Proof of Concept Established

    TARGET MARKETS MODEL FOR STUDY ALGRX 4975: PROOF OF CONCEPT ESTABLISHED Delay progression to surgery Musculoskeletal Pain Tendonitis / Osteoarthritis Complex Regional Pain Syndrome (CRPS) Local Neuropathic Pain Morton’s Neuroma Joint Replacement Post-Surgical Pain Bunionectomy

  29. Slide 29: Morton's Neuroma

    MORTON’S NEUROMA Type of localized post- trauma neuropathic pain Painful foot condition that typically occurs as a result of: – Running – Wearing high narrow shoes – Excessive standing Neuroma (thickened nerve tissue) – Forms as a result of injury to one of the nerves that leads to the toes – Leads

  30. Slide 30: Phase 2 Results: Morton's Neuroma

    PHASE 2 RESULTS: MORTON’S NEUROMA Objectives – Confirm efficacy, safety and tolerability of ALGRX 4975 vs. placebo administered by single injection into neuroma Design and population – U.S. randomized, double-blind, placebo-controlled – 58 subjects of either gender at two U.S. clinical trial sites A

  31. Slide 31: Commercial Opportunities for ALGRX 4975

    COMMERCIAL OPPORTUNITIES FOR ALGRX 4975

  32. Slide 32: ALGRX 4975: U.S. Post-Surgical and Neuropathic Pain Markets

    PROCEDURE NUMBERS ALGRX 4975: U.S. POST-SURGICAL AND NEUROPATHIC PAIN MARKETS POST-SURGICAL PAIN Bunionectomy 709,000 Cholecystectomy 1,230,000 Total knee replacement 412,000 Total hip replacement 346,000 Hernia repair 825,000 Hysterectomy 789,090 LOCAL NEUROPATHIC PAIN 1,269,000 TOTAL 5,580,090

  33. Slide 33: Post-Op Pain Drug Comparison

    Opioids ALGRX 4975 POST-OP PAIN DRUG COMPARISON Hours Weeks Duration Rapid Rapid Onset of action Respiratory depression, nausea, vomiting, ileus Cannot inject near large nerves Safety Frequent Single application Dosing +++ +++ Efficacy

  34. Slide 34: ALGRX 4975: Post-Operative Pain Market

    ALGRX 4975: POST-OPERATIVE PAIN MARKET U.S. post-operative pain market: $1.7 billion Virtually all patients experience some level of pain post operatively Pain in hospital associated with increased length of stay, longer recovery times, poorer patient outcomes

  35. Slide 35: Post-Trauma Neuropathic Pain: Background

    POST-TRAUMA NEUROPATHIC PAIN: BACKGROUND Approximately 1.2 million Americans suffer from a localized form of neuropathic pain resulting from trauma or surgery – Pain lasting months and often severe and debilitating Occurs following 10% of general and 30% of orthopedic surgeries – Most commonly assoc

  36. Slide 36: ALGRX 4975: Neuropathic Pain Market

    ALGRX 4975: NEUROPATHIC PAIN MARKET No drugs indicated for Morton’s neuroma or other post trauma neuropathic pain syndromes – Off label usage of Neurontin, Lidoderms, antidepressants and opioids U.S. neuropathic pain market: $1.9 billion Despite concomitant treatment with several drugs with differen

  37. Slide 37: ALGRX 4975: Blockbuster Potential

    ALGRX 4975: BLOCKBUSTER POTENTIAL Significant unmet medical need Attractive product profile Large surgical volume Small target audience Specialized sales forces

  38. Slide 38: Avrina (NF-kB Decoy) for Eczema

    AVRINA™ (NF- K B DECOY) FOR ECZEMA

  39. Slide 39: Common, Chronic Problem

    COMMON, CHRONIC PROBLEM Eczema (Atopic Dermatitis) – Red, cracked, and unbearably itchy skin caused by excess inflammation in the skin – Makes the person more susceptible to infection 90% of people with AD have staph bacteria on their skin compared to <5% of people without AD – Affects about 15 mill

  40. Slide 40: Attractive Indication

    ATTRACTIVE INDICATION Unmet medical need – Existing therapies are not satisfactory (steroid and calcineurin inhibitors) – Safety issues with long-term application of steroids, especially in children, and black box warning for cancer risk on calcineurin inhibitors Strong preclinical data showing effe

  41. Slide 41: Lack of Rebound with NF-kB Decoy

    Stop Treatment LACK OF REBOUND WITH NF- K B DECOY Start Daily Treatment Placebo NF- K B Decoy Betamethasone Days

  42. Slide 42: Drug Comparison

    Steroids Calcineurin Inhibitors NF- B Decoy DRUG COMPARISON None Limits use None Skin-thinning ++ +++ +++ Onset of action Black box warning for cancer risk May cause significant side effects Limited Systemic exposure Frequent Once/twice a day Short-term +++ Occasional None Rebound Twice a day Short-

  43. Slide 43: Commercial Opportunity

    Total Dollars COMMERCIAL OPPORTUNITY $0 $100 $200 $300 $400 $500 $600 $700 $800 $900 Corticosteroids Protopic Elidel Focused Prescriber Base •10-20% of all dermatological visits •70% of all pediatric visits to a dermatologist Growing Market with new, premium priced drugs Family Practice 9% Internal

  44. Slide 44: AlgoRx Pharmaceuticals, Inc. / Corgentech

    Algok @ Pharmaceuticals, Inc. CORGENTECH

  45. Slide 45: ALGRX 1207

    ALGRX 1207 IND-enabling studies underway New chemical class of local anesthetic for topical analgesia Deep, rapid penetration of the skin and long duration of action Addresses a wide variety of procedures including: – Neuropathic pain – Dermatological surgery – Surgical incisions

  46. Slide 46: ALGRX 1207: Novel Local Anesthetic

    Rapid, complete, and long-lasting topical anesthesia without exotic delivery Unique non-clinical results in relevant models ALGRX 1207: NOVEL LOCAL ANESTHETIC Time ( minutes ) after single application Time ( hours ) after single application Rapid Onset of Complete Anesthesia Long Duration of Pain Re

  47. Slide 47: ALGRX 1207: Target Market

    Drug 2004 US Sales ($ in MM) Patient Cost/ Year OxyContin $1,500 $2,730 Neurontin $2,198 $2,430 Duragesic $1,266 $2,420 Lidoderm $309 $1,450 Drug 2004 US Sales ($ in MM) Patient Cost/ Year ALGRX 1207:TARGET MARKET OxyContin $1,500 $2,730 Neurontin $2,198 $2,430 Duragesic $1,266 $2,420 Lidoderm $309

  48. Slide 48: For additional information about the proposed merger

    For additional information about the proposed merger of Corgentech and AlgoRx, please visit www.corgentech.com and the other sources described in our forward looking statement slide.

Algorx Pharmaceuticals — Merger or Acquisition (November 2005) on 6ix